Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456), a Chinese pharmaceutical company, has declared plans to invest USD 42 million in the establishment of a wholly-owned subsidiary in Japan that will offer Contract Research Organization (CRO) services. This strategic expansion will be executed through Jiuzhou’s existing wholly-owned subsidiary, Raybow Life Sciences（Singapore）Pte Ltd.
The new subsidiary is designed to reduce the service radius for international customers, allowing Jiuzhou to engage in the research and development (R&D) processes of its overseas clients at an earlier stage. This move is anticipated to yield more customer resources and orders, and also to steer the domestic CDMO (Contract Development and Manufacturing Organization) business of the company. Moreover, the establishment of this platform is expected to enhance technical exchanges and cooperation, and to draw in global talent to the company.- Flcube.com
